Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap
… visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) … editing levels in retinal organoid models. ProQR will develop selected genetic eye disease targets with Axiomer ® , …
… financial statements, the potential exercise of share options and the conversion of preferred shares into ordinary … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. …
… financial statements, the potential exercise of share options and the conversion of preferred shares into ordinary … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. …
… financial statements, the potential exercise of share options and the conversion of preferred shares into ordinary … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. …
… in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic … lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today … the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new …